BRCTF (BioArctic AB) Land And Improvements : $0.0 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is BioArctic AB Land And Improvements?

BioArctic AB's land and improvements for the quarter that ended in Mar. 2025 was $0.0 Mil.

BioArctic AB Land And Improvements Historical Data

The historical data trend for BioArctic AB's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioArctic AB Land And Improvements Chart

BioArctic AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Get a 7-Day Free Trial

BioArctic AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

BioArctic AB Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

BioArctic AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (OTCPK:BRCTF) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

BIOA B:Sweden BIOABs:UK 0RV2:UK B9A:Germany

Address

Warfvinges vag 35, Stockholm, SWE, SE-112 51

Website

https://www.bioarctic.se

BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.